Home › Trial NCT02558816
A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
- Trial IDNCT02558816
- StatusCompleted
- PhasePhase 1/2
- Study typeInterventional
- SponsorNantes University Hospital
- Enrollment48
- Start date2015-10-14
- ConditionsMantle Cell Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.